Patent · US Active

CD37-binding molecules and immunoconjugates thereof

US9447189B2 · kind B2 · utility

7Cited by

7References

27Claims

0Family size

Assignee

IMMUNOGEN, INC. · US

Inventors

Jutta Deckert · Lexington, US
Julianto Setiady · Waltham, US
Peter U. Park · Lexington, US

Key dates

Filing date	Mar 30, 2012
Grant date	Sep 20, 2016
Priority date	—
Expiry date	Oct 25, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Methods of using CD37 agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 to deplete B-cells (e.g., non-cancerous B-cells) and methods of treating autoimmune and inflammatory diseases are further provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.